Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant Acinetobacter baumannii in Patients with Normal Renal Clearance: Can It Be a Treatment Option?,Microbial Drug Resistance

当前位置： X-MOL 学术 › Microb. Drug Resist. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant Acinetobacter baumannii in Patients with Normal Renal Clearance: Can It Be a Treatment Option?
Microbial Drug Resistance ( IF 2.6 ) Pub Date : 2021-04-15 , DOI: 10.1089/mdr.2020.0197
Sazlyna Mohd Sazlly Lim _{1,

2} , Aaron J Heffernan _{1,

3} , Jason A Roberts _{1,

4,

5} , Fekade B Sime _{1,

4}

Affiliation

Background and Objective: Combination therapy may be a treatment option against carbapenem-resistant Acinetobacter baumannii (CR-AB) infections. In this study, we explored the utility of fosfomycin in combination with meropenem (FOS/MEM) against CR-AB isolates.

中文翻译：

美罗培南磷霉素联合治疗肾清除率正常患者抗碳青霉烯类鲍曼不动杆菌的药效学分析：能否成为治疗选择？

背景与目的：联合治疗可能是抗碳青霉烯类鲍曼不动杆菌（CR-AB）感染的一种治疗选择。在这项研究中，我们探索了磷霉素与美罗培南 (FOS/MEM) 联合使用对 CR-AB 分离株的作用。

更新日期：2021-04-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>